BACKGROUND: The process of cervical ripening can involve the use of up to four (25mcg) tablets of misoprostol before a favourable Bishop score is achieved which takes 24hours (6hourly dosage) and in some cases a favourable Bishop score may not be achieved leading to prolonged hospitalization, failed induction, and an increased caesarean delivery rate. Inhibitory impulses, in the form of spasm have been postulated to impair the dilatation of the cervix and spasmolytic drugs are frequently employed to overcome such spasms thus reducing the duration of labour. One of these spasmolytic drugs is hyoscine butylbromide and the addition of this drug to the process of cervical ripening to determine if a favourable Bishop score can be achieved within a shorter time and also reduce the duration of labour will go a long way in benefiting the obstetrician and the patients. OBJECTIVES: The purpose of the study was to compare the efficacy and safety of combining intravenous hyoscine with vaginal misoprostol against vaginal misoprostol alone in cervical ripening amongst pregnant women scheduled for induction of labour. METHODOLOGY: This was a randomised controlled trial involving 92 consenting participants in which 46 participants had a combination of intravenous hyoscine butyl bromide and vaginal misoprostol for cervical ripening while the other 46 received placebo and vaginal misoprostol. The primary outcomes included duration of time to achieve a favourable Bishop score, onset of active phase of labour and delivery time from insertion of first dose of misoprostol and xiii doses of misoprostol needed. Secondary outcome measures included the rate of caesarean and vaginal deliveries, possible side effects from the drugs and the babies APGAR scores at birth. Statistical Package for Social Sciences (SPSS) version 21.0 (IBM, Chicago, USA) was used for statistical analysis.